|
ALBUQUERQUE,
N.M.-- John Cousins, president of cancer diagnostics company
Biomoda, Inc., has been elected to the Board of Directors of the
New Mexico Biotechnology and Biomedical Association (NMBio).
“I
know firsthand how receptive New Mexico is to the bioscience
industry,” Cousins said. “NMBio plays a critical role in
promoting our industry and our region by providing a platform for
interaction between the science side and the business side of
biotech.”
NMBio
was established to provide a forum for information exchange in the
life sciences, develop initiatives to enhance small business
success, provide education and outreach, help establish
collaborations, and publicize the New Mexico bioscience industry.
NMBio is an affiliate of the national Biotechnology Industry
Organization.
As
a member of the NMBio Board of Directors, Cousins joins a
volunteer group of scientists, academics and other professionals
dedicated to the advancement of bioscience in New Mexico and the
promotion of New Mexico’s capabilities internationally. During
his two-year term, Cousins will be involved in NMBio-sponsored
programs and events, policy development and a variety of committee
assignments.
“Biomoda
has benefited from our affiliation with NMBio and I look forward
to building the biotech community in New Mexico by helping other
companies in the bioscience sector succeed,” Cousins said.
Biomoda’s
initial product is a diagnostic assay for the detection of
early-stage lung cancer. Currently in Phase II clinical trials,
the CyPath® assay is a porphyrin-based compound that
preferentially binds to cancer cells and causes them to fluoresce
red under ultraviolet light. CyPath® is for investigational use
only pending approval by the U.S. Food and Drug Administration
(FDA).
About
Biomoda
Biomoda
(OTC BB: BMOD) (www.biomoda.com)
is a cancer diagnostics company focused on the development of
accurate, inexpensive and noninvasive tests for the early
detection of cancer. Current research and development operations,
laboratory functions for both microscopy and assay formulation,
and administrative offices are located in Albuquerque, NM.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are based on
estimates, projections, beliefs and assumptions of Biomoda
management at the time of such statements and are not guarantees
of future performance. Forward-looking statements involve risks
and uncertainties in predicting future results and conditions.
Actual results could differ materially from those projected in
these forward-looking statements due to a variety of factors,
including, without limitation, the acceptance by customers of our
products, our ability to develop new products cost-effectively,
our ability to raise capital in the future, the development by
competitors of products using improved or alternative technology,
the retention of key employees and general economic conditions.
Forward-looking statements are made as of the date of this press
release and are subject to change without notice.
CONTACT:
Biomoda, Inc.
John
Cousins
505.821.0875
investor@biomoda.com
|
